Company Performance Metrics
- Alethia x Alethia Young: Chief Financial OfficerPast Role: Cantor Fitzgerald, Large Cap Biotech Analyst and Head of Healthcare Research
Phil Gutry: Chief Business Officer, Head of Finance & Investor RelationsPast Role: Regeneron, Executive Director, Business Development
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to
transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations.